全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

玻璃体腔注射康柏西普联合曲安奈德与单用康柏西普治疗青年CRVO的临床疗效比较
Comparison of Clinical Efficacy of Intravitreal Injection of Conbercept Combined with Triamcinolone Acetonide and Conbercept Alone on the Treatment of CRVO in Young Adults

DOI: 10.12677/ACM.2020.1010361, PP. 2393-2400

Keywords: 康柏西普，曲安奈德，视网膜中央静脉阻塞，青年，有效性
Conbercept, Triamcinolone Acetonide, Central Retinal Vein Occlusion, Young Adults, Efficacy

Full-Text   Cite this paper   Add to My Lib

Abstract:

背景：视网膜中央静脉阻塞(central retinal vein occlusion CRVO)继发黄斑水肿治疗的理论基础是降低VEGF (vascular endothelial growth factor)的作用，中青年CRVO的发病机制与炎症密切相关，康柏西普联合曲安奈德(triamcinolone acetonide, TA)在青年CRVO治疗方面的研究较少。目的：比较康柏西普(Conbercept)联合曲安奈与单用康柏西普治疗青年CRVO的临床疗效及安全性。方法：采用回顾性研究，选择2015.06~2019.04于淄博市中心医院眼科行康柏西普联合1 mg TA玻璃体腔注射治疗的20例(20眼)青年CRVO患者，作为观察组，同时间行0.5 mg (0.05 ml)康柏西普玻璃体腔注射治疗的20例(20眼)青年CRVO患者作为对照组。观察两组的视力、眼压、裂隙灯、眼底检查、眼底荧光血管造影和光学相干断层扫描等指标变化情况及有无全身不良反应，并比较治疗前及治疗后1个月、3个月、6个月的最佳矫正视力(best-correct visual acuity, BCVA) EDTRS字母数、黄斑中心视网膜厚度(central retina thickness, CRT)、眼压及两组的注射次数。结果：两组人口基线特征相比无差异(P > 0.05)，观察组治疗前BCVA为65.35 ± 6.11，治疗后1、3、6个月的BCVA分别为75.40 ± 4.47、76.05 ± 3.71、75.85 ± 3.88，较治疗前均有提高；对照组治疗前BCVA为67.30 ± 5.99，治疗后1、3、6个月的BCVA分别为73.00 ± 3.84、73.00 ± 5.53、76.40 ± 3.25，较治疗前均有提高，观察组治疗3个月BCVA高于对照组(P < 0.05)，治疗6个月两组BCVA组间比较无差异(P > 0.05)，对照组较治疗前提高>10个字母8例，提高5~10个字母12例，观察组较治疗前提高>10个字母11例，提高5~10个字母7例，提高<5个字母2例。观察组治疗前基线CRT为(518.85 ± 30.67) μm，治疗后1、3、6个月的CRT分别为(271.65 ± 75.31)、(260.20 ± 68.15)、(271.35 ± 80.82) μm，均低于治疗前；对照组治疗前CRT为(519.45 ± 39.54) μm，治疗后1、3、6个月的CRT分别为(312.05 ± 93.55)、(317.35 ± 97.27)、(276.30 ± 73.09) μm，均低于治疗前，观察组治疗3个月CRT低于对照组(P < 0.05)。对照组治疗前眼压为(13.90 ± 2.75) mmHg，治疗后1个月、3个月、6个月眼压为(15.05 ± 2.31)、(15.25 ± 2.51)、(15.95 ± 2.42) mmHg，与治疗前相比，差异无统计学意义(P > 0.05)，观察组治疗前眼压为(14.65 ± 1.93) mmHg，治疗后1个月、3个月、6个月眼压为(15.50 ± 2.01)、(15.10 ± 2.73)、(15.05 ± 2.70) mmHg，与治疗前相比，差异无统计学意义(P > 0.05)，观察组与对照组治疗后各时间点眼压相比，差异无统计学意义。对照组注射2~4 (3.00 ± 0.65)次，观察组注射1~2 (1.25 ± 0.44)次，两组有统计学差异(P < 0.05)。两组均未发生青光眼、白内障、眼内炎等眼部并发症及全身不良反应。结论：康柏西普联合曲安奈德与单用康柏西普玻璃体腔注射均能减轻青年型CRVO患者的黄斑水肿，提高矫正视力。与单用康柏西普相比，康柏西普联合曲安奈德能减少注射次数。
Background: The theoretical basis for treating macular edema secondary to central retinal vein occlusion is to reduce the effect of vascular endothelial growth factor. The pathogenesis of central retinal vein occlusion in young and middle-aged people is closely related to inflammation. The research of the treatment of CRVO in young adults with intravitreal injection of conbercept combined with triamcinolone acetonide is rather little. Objective: To compare the clinical efficacy and safety of intravitreal injection of conbercept combined with triamcinolone acetonide and conbercept alone in the treatment of CRVO in young adults. Methods: A retrospective study was designed. Twenty cases (20 eyes) of young patients with central retinal vein occlusion who received intravitreal injection of conbercept combined with 1 mg triamcinolone acetonide in Ophthalmology Department of Zibo Central Hospital from June 2015 to April 2019 were

References

[1]  王润生, 吕沛霖. 激光光凝治疗非典型缺血型视网膜静脉阻塞178例[J]. 国际眼科杂志, 2005, 5(3): 493-495.
[2]  Ascaso, F.J., Huerva, V. and Grzybowski, A. (2014) The Role of Inflammation in the Pathogenesis of Macular Edema Secondary to Retinal Vascular Diseases. Mediators of Inflammation, 2014, Article ID: 432685.
https://doi.org/10.1155/2014/432685
[3]  Fegan, C.D. (2002) Central Retinal Vein Occlusion and Thrombophilia. Eye (Lond), 16, 98-106.
https://doi.org/10.1038/sj.eye.6700040
[4]  Penfold, P.L., Wen, L., Madigan, M.C., et al. (2000) Triamcinolone Acetonide Modulates Permeability and Intercellular Adhesion Molecule-1 (ICAM-1) Expression of the ECV304 Cell Line: Implications for Macular Degeneration. Clinical & Experimental Immunology, 121, 458-465.
https://doi.org/10.1046/j.1365-2249.2000.01316.x
[5]  Aiello, L.P., Avery, R.L., Arrigg, P.G., et al. (1994) Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders. The New England Journal of Medicine, 331, 1480-1487.
https://doi.org/10.1056/NEJM199412013312203
[6]  Wu, Z.G., Zhou, P., Li, X.X., et al. (2013) Structural Characterization of a Recombinant Fusion Protein by Instrumental Analysis and Molecular Modeling. PLoS ONE, 8, e57642.
https://doi.org/10.1371/journal.pone.0057642 http://med.wanfangdata.com.cn/Paper/Search?q=Structural%20characterization%20of%20a%20recombinant% 20fusion%20protein%20by%20instrumental%20analysis%20and% 20molecular%20modeling
[7]  刘军, 沈志华, 秦波, 等. 玻璃体腔联合注射康柏西普及曲安奈德治疗中青年视网膜中央静脉阻塞初步临床观察[J]. 临床眼科杂志, 2016, 24(3): 215-218.
[8]  Pielen, A., Feltgen, N., Isserstedt, C., et al. (2013) Efficacy and Safety of Intravitreal Therapy in Macular Edema Due to Branch and Central Retinal Vein Occlusion: A Systematic Review. PLoS ONE, 8, e78538.
https://doi.org/10.1371/journal.pone.0078538
[9]  Zhang, M., Zhang, J., Yan, M., et al. (2008) Recombinant Anti-Vascular Endothelial Growth Factor Fusion Protein Efficiently Suppresses Choridal Neovasularization in Monkeys. Molecular Vision, 14, 37-49. http://med.wanfangdata.com.cn/Paper/Search?q=Recombinant%20anti-vascular%20endothelial%20growth%20factor%20fusion% 20protein%20efficiently%20suppresses%20choridal% 20neovasularization%20in%20monkeys
[10]  徐娜, 高荣玉, 徐鑫彦, 等. 玻璃体腔注射康柏西普对视网膜分支静脉阻塞引发的不同类型黄斑水肿的疗效[J]. 中华实验眼科杂志, 2018, 36(8): 619-624. http://med.wanfangdata.com.cn/Paper/Search?q=%E7%8E%BB%E7%92%83%E4%BD%93%E8%85%94%E8%81%94%E5%90% 88%E6%B3%A8%E5%B0%84%E5%BA%B7%E6%9F%8F%E8%A5%BF%E6%99% AE%E5%8F%8A%E6%9B%B2%E5%AE%89%E5%A5%88%E5%BE%B7%E6%B2% BB%E7%96%97%E4%B8%AD%E9%9D%92%E5%B9%B4%E8%A7%86%E7%BD% 91%E8%86%9C%E4%B8%AD%E5%A4%AE%E9%9D%99%E8%84%89%E9%98% BB%E5%A1%9E%E5%88%9D%E6%AD%A5%E4%B8%B4%E5%BA%8A%E8%A7% 82%E5%AF%9F
[11]  Sibel, D., Ali, S.M., Alpaslan, A.M., et al. (2016) A Rare Cause of Unilateral Central Retinal Vein Occlusion in a Young Patient: Type III Mixed Cryoglobulinemia. Case Reports in Ophthalmological Medicine, 2016, Article ID: 1949362. http://med.wanfangdata.com.cn
https://doi.org/10.1155/2016/1949362
[12]  Gregori, N.Z., Rosenfeld, P.J., Puliafito, C.A., et al. (2006) One-Year Safety and Efficacy of Intravitreal Triamcinolone Acetonide for the Management of Macular Edema Secondary to Central Retinal Vein Occlusion. Retina, 26, 889-895.
https://doi.org/10.1097/01.iae.0000237111.82357.30
[13]  王丽丽, 张雯, 李立婕, 等. 贝伐单抗与曲安耐德玻璃体腔注射治疗糖尿病黄斑水肿近期疗效的比较[J]. 中华实验眼科杂志, 2011, 29(6): 559-563.
[14]  马锋伟, 杜翠云, 程美红, 等. 康柏西普与曲安奈德玻璃体腔注射治疗视网膜中央静脉阻塞继发黄斑水肿临床疗效的比较[J]. 中华实验眼科杂志, 2016, 34(9): 837-841. http://med.wanfangdata.com.cn
[15]  李静, 姚霞, 周国宏. 玻璃体内注射康柏西普治疗继发性黄斑水肿的效果观察[J]. 中华眼外伤职业眼病杂志, 2020, 42(1): 22-25. http://med.wanfangdata.com.cn/Author/General/A000770016
[16]  Fan, C.F., Wang, Y., Ji, Q., et al. (2014) Comparison of Clinical Efficacy of Intravitreal Ranibizumab with and without Triamcinolone Acetonide in Macular Edema Secondary to Central Retinal Vein Occlusion. Current Eye Research, 39, 938-943.
https://doi.org/10.3109/02713683.2014.885533

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133